Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.37 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17936829 | 1.00 | HDAC1 (0.37) | HDAC1HDAC2PDK2PDK1SETD7 | |
| SCHEMBL17925729 | 1.00 | HDAC1 (0.37) | HDAC1HDAC2PDK2PDK1SETD7 | |
| SCHEMBL17936845 | 0.87 | PDK2 (0.38) | PDK2PDK1ELANENTRK1GPR119 | |
| SCHEMBL28361066 | 0.87 | HDAC1 (0.38) | HDAC1HDAC2ELANETACR1POLB | |
| SCHEMBL17936815 | 0.87 | PDK2 (0.40) | PDK2PDK1ELANENTRK1GPR119 | |
| SCHEMBL17936915 | 0.85 | ELANE (0.36) | HDAC1SETD7ELANENTRK1GPR119 | |
| SCHEMBL19632326 | 0.81 | GPR119 (0.38) | HDAC1SETD7ELANEGPR119 | |
| SCHEMBL21058315 | 0.81 | GPR119 (0.38) | HDAC1SETD7ELANEGPR119 | |
| SCHEMBL30622815 | 0.80 | CSNK1D (0.37) | HDAC1HDAC2PDK2SETD7 | |
| SCHEMBL30622940 | 0.80 | CSNK1D (0.37) | HDAC1HDAC2PDK2SETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-9890167-B2 | Pyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890167-B2 | Pyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | CYP3A5, HAVCR2, HCCS | HDAC1 614/4885HDAC2 599/4885PDK2 476/4885 |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HAVCR2, NR1H4, ZC3HAV1 | HDAC1 443/4885HDAC2 630/4885PDK2 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.